166 related articles for article (PubMed ID: 28116790)
21. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.
Schayowitz A; Sabnis G; Njar VC; Brodie AM
Mol Cancer Ther; 2008 Jan; 7(1):121-32. PubMed ID: 18202015
[TBL] [Abstract][Full Text] [Related]
23. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
[TBL] [Abstract][Full Text] [Related]
24. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
25. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer.
Wang Y; Kreisberg JI; Ghosh PM
Curr Cancer Drug Targets; 2007 Sep; 7(6):591-604. PubMed ID: 17896924
[TBL] [Abstract][Full Text] [Related]
26. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines.
Dizeyi N; Hedlund P; Bjartell A; Tinzl M; Austild-Taskén K; Abrahamsson PA
Urol Oncol; 2011; 29(4):436-45. PubMed ID: 19926313
[TBL] [Abstract][Full Text] [Related]
27. Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.
Toren P; Kim S; Johnson F; Zoubeidi A
PLoS One; 2016; 11(4):e0152861. PubMed ID: 27046225
[TBL] [Abstract][Full Text] [Related]
28. Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells.
Varisli L; Gonen-Korkmaz C; Syed HM; Bogurcu N; Debelec-Butuner B; Erbaykent-Tepedelen B; Korkmaz KS
Mol Cell Endocrinol; 2012 Mar; 350(1):107-17. PubMed ID: 22155408
[TBL] [Abstract][Full Text] [Related]
29. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
[TBL] [Abstract][Full Text] [Related]
30. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Liu Z; Zhu G; Getzenberg RH; Veltri RW
J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
[TBL] [Abstract][Full Text] [Related]
31. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.
Yan L; Xing Z; Guo Z; Fang Z; Jiao W; Guo X; Xu Z; Fang Z; Liu Z
PLoS One; 2013; 8(2):e55790. PubMed ID: 23409045
[TBL] [Abstract][Full Text] [Related]
34. Estrogen Receptor Signaling Pathways Involved in Invasion and Colony Formation of Androgen-Independent Prostate Cancer Cells PC-3.
Lombardi APG; Cavalheiro RP; Porto CS; Vicente CM
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503805
[TBL] [Abstract][Full Text] [Related]
35. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
[TBL] [Abstract][Full Text] [Related]
36. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer.
Wu C; Huang J
J Biol Chem; 2007 Feb; 282(6):3571-83. PubMed ID: 17148458
[TBL] [Abstract][Full Text] [Related]
37. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
38. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
39. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Benitez DA; Pozo-Guisado E; Clementi M; Castellón E; Fernandez-Salguero PM
Br J Cancer; 2007 May; 96(10):1595-604. PubMed ID: 17486135
[TBL] [Abstract][Full Text] [Related]
40. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
